Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng et al

Affiliations

• ¹ Division of Rheumatology, Department of Medicine, Columbia University Medical Center, New York, New York, USA dpappas@corrona.org.
• ² Corrona, Albany Medical College and The Center for Rheumatology, Waltham, Massachusetts, USA.
• ³ Medical Affairs, Regeneron Pharmaceuticals, Tarrytown, New York, USA.
• ⁴ Medical Affairs, Sanofi, Bridgewater, New Jersey, USA.
• ⁵ Medical Analytics, Regeneron Pharmaceuticals, Tarrytown, New York, USA.
• ⁶ Real World Evidence Generation, Sanofi Genzyme, Cambridge, Massachusetts, USA.
• ⁷ Health Economics and Value Assessment, Sanofi, Bridgewater, New Jersey, USA.